Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol IL6 contributors: mct - updated : 03-12-2018
HGNC name interleukin 6 (interferon, beta 2)
HGNC id 6018
corresponding disease(s)
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
constitutional     --over  
in inflammatory bowel diseases
tumoral     --over  
in inflammatory breast cancer
constitutional     --over  
in midlife predicts cognitive decline
constitutional     --over  
in primary and secondary models of lymphedema
constitutional     --over  
increased in the plasma of patients with cerebral arteriovenous malformation
constitutional     --over  
in hepatitis B patients
  • susceptibility in carotid artery atherosclerosis and osteopenia
  • to Kaposi sarcoma
  • to juvenile rheumatoid arthritis (OMIM: 604302)
  • to cerebral palsy in term and near-term infants (CP)
  • to type 2 diabetes
  • to osteoporosis (bone mineral density)
  • elevated IL-6 levels are strongly associated with future cardiac events and mortality in a population with stable coronary artery disease during a long-term follow-up
  • to sporadic Alzheimer's disease
  • Variant & Polymorphism other
  • in juvenile rheumatoid arthritis
  • G/C promoter polymorphism in NIDDM (in native Americans and Caucasians)
  • C174G associated with bone loss in postmenopausal women
  • -572C/G polymorphism of IL6 gene promoter region is associated with AD, and G allele is an independent protective factor for AD
  • functional polymorphism in the IL6 gene is a risk factor for CP among term and near-term infants
  • Candidate gene
  • cerebrospinal fluid (CSF) IL6 may help to differentiate multiple sclerosis (MS) from other inflammatory neurological diseases (OIND)
  • Therapy target
    antibodies specific as therapeutic targets in rheumatoid arthritis
    therapeutic neutralization of IL6 for treatment of certain diseases may represent a risk if the patient is HBV-infected
    use of therapeutic strategies aimed at antagonizing CCL2 or IL6 signaling in diabetic kidney injury
    potential therapeutic target in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA)